HealthEquity (NASDAQ:HQY) Price Target Raised to $122.00

HealthEquity (NASDAQ:HQY) had its price target upped by Citizens Jmp from $117.00 to $122.00 in a research report released on Thursday,Benzinga reports. They currently have a market outperform rating on the stock.

HQY has been the topic of a number of other research reports. Citigroup restated an “outperform” rating on shares of HealthEquity in a report on Thursday. JPMorgan Chase & Co. lifted their price target on HealthEquity from $125.00 to $126.00 and gave the company an “overweight” rating in a research note on Wednesday, September 3rd. BMO Capital Markets started coverage on HealthEquity in a research note on Thursday, November 13th. They issued a “market perform” rating and a $100.00 price objective for the company. KeyCorp dropped their target price on HealthEquity from $125.00 to $120.00 and set an “overweight” rating on the stock in a report on Wednesday, October 8th. Finally, JMP Securities set a $122.00 target price on HealthEquity in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $120.43.

HealthEquity Trading Down 1.2%

NASDAQ:HQY opened at $94.51 on Thursday. HealthEquity has a 12 month low of $74.07 and a 12 month high of $116.65. The company has a current ratio of 4.13, a quick ratio of 4.23 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $8.07 billion, a price-to-earnings ratio of 43.35, a PEG ratio of 1.36 and a beta of 0.18. The firm has a fifty day simple moving average of $96.37 and a two-hundred day simple moving average of $96.82.

HealthEquity (NASDAQ:HQY) last announced its quarterly earnings data on Wednesday, December 3rd. The company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.11. The firm had revenue of $322.16 million for the quarter, compared to analyst estimates of $320.92 million. HealthEquity had a net margin of 14.86% and a return on equity of 12.94%. The business’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.78 earnings per share. HealthEquity has set its FY 2026 guidance at 3.870-3.950 EPS. Analysts expect that HealthEquity will post 2.32 EPS for the current fiscal year.

Insider Activity at HealthEquity

In related news, EVP Delano Ladd sold 1,500 shares of the company’s stock in a transaction on Thursday, November 20th. The stock was sold at an average price of $104.56, for a total transaction of $156,840.00. Following the completion of the sale, the executive vice president owned 75,479 shares in the company, valued at approximately $7,892,084.24. This represents a 1.95% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Michael Henry Fiore sold 1,781 shares of the stock in a transaction dated Tuesday, October 7th. The shares were sold at an average price of $88.21, for a total value of $157,102.01. Following the completion of the transaction, the executive vice president directly owned 49,795 shares in the company, valued at approximately $4,392,416.95. This represents a 3.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 10,781 shares of company stock valued at $1,016,707 in the last three months. 1.50% of the stock is owned by insiders.

Institutional Trading of HealthEquity

Institutional investors and hedge funds have recently modified their holdings of the company. Cetera Investment Advisers raised its stake in shares of HealthEquity by 47.3% during the 1st quarter. Cetera Investment Advisers now owns 5,260 shares of the company’s stock worth $465,000 after acquiring an additional 1,688 shares in the last quarter. Federated Hermes Inc. increased its position in shares of HealthEquity by 18.8% during the first quarter. Federated Hermes Inc. now owns 9,756 shares of the company’s stock worth $862,000 after purchasing an additional 1,547 shares in the last quarter. US Bancorp DE increased its position in shares of HealthEquity by 1.3% during the first quarter. US Bancorp DE now owns 18,350 shares of the company’s stock worth $1,622,000 after purchasing an additional 244 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in shares of HealthEquity by 47.1% during the 1st quarter. PNC Financial Services Group Inc. now owns 13,063 shares of the company’s stock valued at $1,154,000 after purchasing an additional 4,183 shares during the last quarter. Finally, New Age Alpha Advisors LLC boosted its position in shares of HealthEquity by 755.8% in the 1st quarter. New Age Alpha Advisors LLC now owns 22,175 shares of the company’s stock worth $1,960,000 after purchasing an additional 19,584 shares in the last quarter. 99.55% of the stock is currently owned by institutional investors.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.